CDNA vs. CSTL, CELC, FLGT, SERA, BDSX, GTH, PSNL, BNR, VRDN, and VCYT
Should you be buying CareDx stock or one of its competitors? The main competitors of CareDx include Castle Biosciences (CSTL), Celcuity (CELC), Fulgent Genetics (FLGT), Sera Prognostics (SERA), Biodesix (BDSX), Genetron (GTH), Personalis (PSNL), Burning Rock Biotech (BNR), Viridian Therapeutics (VRDN), and Veracyte (VCYT). These companies are all part of the "medical laboratories" industry.
CareDx (NASDAQ:CDNA) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, community ranking, profitability and institutional ownership.
CareDx has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.
92.6% of Castle Biosciences shares are owned by institutional investors. 4.2% of CareDx shares are owned by insiders. Comparatively, 7.7% of Castle Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Castle Biosciences has lower revenue, but higher earnings than CareDx. Castle Biosciences is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.
In the previous week, Castle Biosciences had 3 more articles in the media than CareDx. MarketBeat recorded 9 mentions for Castle Biosciences and 6 mentions for CareDx. Castle Biosciences' average media sentiment score of 0.77 beat CareDx's score of 0.38 indicating that Castle Biosciences is being referred to more favorably in the news media.
CareDx received 341 more outperform votes than Castle Biosciences when rated by MarketBeat users. Likewise, 66.51% of users gave CareDx an outperform vote while only 62.02% of users gave Castle Biosciences an outperform vote.
Castle Biosciences has a net margin of -26.15% compared to CareDx's net margin of -67.88%. Castle Biosciences' return on equity of -14.92% beat CareDx's return on equity.
CareDx presently has a consensus price target of $11.00, indicating a potential upside of 4.96%. Castle Biosciences has a consensus price target of $31.00, indicating a potential upside of 43.05%. Given Castle Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Castle Biosciences is more favorable than CareDx.
Summary
Castle Biosciences beats CareDx on 13 of the 18 factors compared between the two stocks.
Get CareDx News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools